Wall Street analysts forecast that Edwards Lifesciences Corporation (NYSE:EW) will post sales of $833.89 million for the current quarter, Zacks reports. Eight analysts have made estimates for Edwards Lifesciences Corporation’s earnings, with the lowest sales estimate coming in at $822.80 million and the highest estimate coming in at $843.80 million. Edwards Lifesciences Corporation reported sales of $739.40 million in the same quarter last year, which would suggest a positive year over year growth rate of 12.8%. The firm is expected to issue its next earnings report after the market closes on Tuesday, October 24th.

On average, analysts expect that Edwards Lifesciences Corporation will report full-year sales of $833.89 million for the current year, with estimates ranging from $3.37 billion to $3.46 billion. For the next financial year, analysts forecast that the firm will report sales of $3.74 billion per share, with estimates ranging from $3.65 billion to $3.79 billion. Zacks’ sales averages are an average based on a survey of sell-side research analysts that follow Edwards Lifesciences Corporation.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm had revenue of $842.00 million during the quarter, compared to the consensus estimate of $839.16 million. During the same period last year, the business posted $0.76 EPS. The business’s revenue was up 10.9% compared to the same quarter last year.

Several equities analysts have recently commented on EW shares. BidaskClub raised shares of Edwards Lifesciences Corporation from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 22nd. Zacks Investment Research cut shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 26th. BMO Capital Markets reiterated a “buy” rating and set a $132.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, September 1st. Cowen and Company reiterated a “buy” rating and set a $135.00 price target on shares of Edwards Lifesciences Corporation in a research report on Thursday, October 12th. Finally, Barclays PLC boosted their price target on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the company an “equal weight” rating in a research report on Thursday, July 27th. Seven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $120.75.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Anticipate Edwards Lifesciences Corporation (EW) Will Announce Quarterly Sales of $833.89 Million” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/zacks-analysts-anticipate-edwards-lifesciences-corporation-ew-will-announce-quarterly-sales-of-833-89-million/1635636.html.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 108.52 on Tuesday. The firm’s 50-day moving average price is $111.37 and its 200-day moving average price is $111.56. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.45. The firm has a market capitalization of $22.91 billion, a P/E ratio of 32.91 and a beta of 0.62.

In other news, VP Larry L. Wood sold 18,960 shares of the stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $108.54, for a total transaction of $2,057,918.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $114.80, for a total transaction of $3,776,920.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 201,161 shares of company stock worth $22,826,072. Corporate insiders own 2.13% of the company’s stock.

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in Edwards Lifesciences Corporation by 2.0% during the second quarter. Vanguard Group Inc. now owns 20,748,569 shares of the medical research company’s stock valued at $2,453,311,000 after purchasing an additional 406,901 shares during the period. BlackRock Inc. lifted its position in Edwards Lifesciences Corporation by 0.8% during the second quarter. BlackRock Inc. now owns 14,109,514 shares of the medical research company’s stock valued at $1,668,309,000 after purchasing an additional 105,819 shares during the period. State Street Corp lifted its position in Edwards Lifesciences Corporation by 1.7% during the first quarter. State Street Corp now owns 9,388,994 shares of the medical research company’s stock valued at $883,219,000 after purchasing an additional 157,844 shares during the period. Bank of New York Mellon Corp lifted its position in Edwards Lifesciences Corporation by 161.7% during the second quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock valued at $627,207,000 after purchasing an additional 3,277,726 shares during the period. Finally, Winslow Capital Management LLC lifted its position in Edwards Lifesciences Corporation by 0.8% during the first quarter. Winslow Capital Management LLC now owns 2,654,484 shares of the medical research company’s stock valued at $249,707,000 after purchasing an additional 19,887 shares during the period. Institutional investors own 81.90% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Get a free copy of the Zacks research report on Edwards Lifesciences Corporation (EW)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.